Suchergebnisse - "Richardson, Paul G."

PubPharm (764)

1

Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

enthalten in: bioRxiv.org | 2024

von Nadeem, O. | Aranha, M. | Redd, R. | +19

2

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk

enthalten in: Blood cancer journal | 2024

von Callander, N. | Silbermann, R. | Kaufman, J. | +33

3

Author Correction : Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

enthalten in: Nature medicine | 2024

von McMillin, D. | Delmore, J. | Weisberg, E. | +11

ErratumFor: Nat Med. 2010 Apr;16(4):483-9. - PMID 20228816

4

Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone : Patient-reported outcomes from GRIFFIN

enthalten in: American journal of hematology | 2024

von Silbermann, R. | Laubach, J. | Kaufman, J. | +23

5

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

enthalten in: Blood | 2024

von Gulla, A. | Morelli, E. | Johnstone, M. | +26

6

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

enthalten in: British journal of haematology | 2024

von Nooka, A. | Kaufman, J. | Rodriguez, C. | +16

7

Mezigdomide-A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma

enthalten in: Cancers | 2024

von Hartley-Brown, M. | Mo, C. | Nadeem, O. | +3

8

ANCHOR : melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

enthalten in: Haematologica | 2024

von Ocio, E. | Efebera, Y. | Hájek, R. | +12

9

Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma : results from the randomized, open-label, phase III LIGHTHOUSE study

enthalten in: Haematologica | 2024

von Pour, L. | Szarejko, M. | Bila, J. | +13

10

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone : analyses from the phase III OCEAN study

enthalten in: Haematologica | 2024

von Schjesvold, F. | Ludwig, H. | Delimpasi, S. | +15

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[77]